These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 32839843

  • 1. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
    Okubo N, Matsui S, Matsumoto T, Sugimoto T, Hosoi T, Osakabe T, Watanabe K, Takami H, Shiraki M, Nakamura T.
    Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
    [Abstract] [Full Text] [Related]

  • 2. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.
    Miyauchi A, Hamaya E, Yang W, Nishi K, Libanati C, Tolman C, Shimauchi J.
    J Bone Miner Metab; 2021 Mar; 39(2):278-288. PubMed ID: 33057807
    [Abstract] [Full Text] [Related]

  • 3. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C.
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [Abstract] [Full Text] [Related]

  • 4. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J.
    Arch Osteoporos; 2019 Jun 05; 14(1):59. PubMed ID: 31168657
    [Abstract] [Full Text] [Related]

  • 5. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension.
    Cosman F, Oates M, Betah D, Timoshanko J, Wang Z, Ferrari S, McClung MR.
    J Bone Miner Res; 2024 Sep 02; 39(9):1268-1277. PubMed ID: 39041711
    [Abstract] [Full Text] [Related]

  • 6. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.
    Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A, Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris ES, Zanchetta J, Zerbini CA, Libanati C, Cummings SR, FREEDOM Trial.
    J Bone Miner Res; 2012 Mar 02; 27(3):687-93. PubMed ID: 22095631
    [Abstract] [Full Text] [Related]

  • 7. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S.
    Lancet Diabetes Endocrinol; 2017 Jul 02; 5(7):513-523. PubMed ID: 28546097
    [Abstract] [Full Text] [Related]

  • 8. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 9. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
    Khan AA, AbuAlrob H, M'Hiri I, Ali DS, Dandurand K, Said H, Alkassem H, Hakami Y, Hweija I, Iqbal S, Romanovschi M, Mehmood S, Zariffeh H, Guyatt G, Ibrahim Q, Brignardello-Petersen R, Syed HI.
    Endocrine; 2023 Jun 16; 80(3):647-657. PubMed ID: 37186270
    [Abstract] [Full Text] [Related]

  • 10. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N, Shiraki M, Nakamura T.
    Osteoporos Int; 2015 Feb 16; 26(2):765-74. PubMed ID: 25403903
    [Abstract] [Full Text] [Related]

  • 11. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.
    Hans D, McDermott M, Huang S, Kim M, Shevroja E, McClung M.
    Osteoporos Int; 2023 Jun 16; 34(6):1075-1084. PubMed ID: 36862192
    [Abstract] [Full Text] [Related]

  • 12. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
    Yang L, Kang N, Yang JC, Su QJ, Liu YZ, Guan L, Liu T, Meng XL, Wang Y, Hai Y.
    Eur Rev Med Pharmacol Sci; 2019 Mar 16; 23(6):2640-2668. PubMed ID: 30964193
    [Abstract] [Full Text] [Related]

  • 13. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
    Pérez Ruixo JJ, Zheng J, Mandema JW.
    J Clin Pharmacol; 2014 May 16; 54(5):503-12. PubMed ID: 24214315
    [Abstract] [Full Text] [Related]

  • 14. Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension.
    Koh JM, Chung DJ, Chung YS, Kang MI, Kim IJ, Min YK, Oh HJ, Park IH, Lee YS, Kravitz B, Waterhouse B, Nino A, Fitzpatrick LA.
    Yonsei Med J; 2016 Jul 16; 57(4):905-14. PubMed ID: 27189284
    [Abstract] [Full Text] [Related]

  • 15. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.
    Arthritis Rheumatol; 2019 Jul 16; 71(7):1174-1184. PubMed ID: 30816640
    [Abstract] [Full Text] [Related]

  • 16. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
    Palacios S, Kalouche-Khalil L, Rizzoli R, Zapalowski C, Resch H, Adachi JD, Gallagher JC, Feldman RG, Kendler DL, Wang A, Wagman RB, Adami S.
    Climacteric; 2015 Jul 16; 18(6):805-12. PubMed ID: 26029985
    [Abstract] [Full Text] [Related]

  • 17. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.
    J Bone Miner Res; 2006 Nov 16; 21(11):1785-90. PubMed ID: 17002571
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.
    J Bone Miner Metab; 2019 Sep 16; 37(5):864-870. PubMed ID: 30868270
    [Abstract] [Full Text] [Related]

  • 19. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ, Naganathan V, Barton I, Grauer A.
    J Bone Miner Res; 2004 Feb 16; 19(2):323-9. PubMed ID: 14969403
    [Abstract] [Full Text] [Related]

  • 20. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
    Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O, Gallagher JC, Farrerons J, Wang A, Franchimont N, San Martin J, Grauer A, McClung M.
    J Clin Endocrinol Metab; 2011 Jun 16; 96(6):1727-36. PubMed ID: 21411557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.